IOL Chemicals & Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

IOL Chemicals & Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 2 September 2026.

Net profit of IOL Chemicals & Pharmaceuticals rose 69.19% to Rs 53.16 crore in the quarter ended March 2026 as against Rs 31.42 crore during the previous quarter ended March 2025. Sales rose 17.37% to Rs 619.45 crore in the quarter ended March 2026 as against Rs 527.78 crore during the previous quarter ended March 2025.

For the full year,net profit rose 36.18% to Rs 137.64 crore in the year ended March 2026 as against Rs 101.07 crore during the previous year ended March 2025. Sales rose 11.54% to Rs 2319.06 crore in the year ended March 2026 as against Rs 2079.21 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 20 May 2026.

The company has enhanced the manufacturing capacity of Ethyl Acetate from 1,00,000 MT per annum to 1,20,000 MT per annum with a capex of about Rs 4 crore. The additional capacity of 20,000 MTPA was completed on 2 March 2026.

The expansion has been undertaken to cater to sustained demand growth across various sectors and to improve margin realisation through optimal operating leverage.

In addition, the company has expanded the manufacturing capacity of Acetic Anhydride from 25,000 MTPA to 32,000 MTPA. The project entails a capital expenditure of about Rs 5.71 crore. The existing facility was operating at above 90% capacity utilisation prior to the expansion. The additional capacity of 7,000 MTPA was commissioned on 2 March 2026.

This expansion is aimed at optimising captive consumption as well as increasing merchant sales.

IOL Chemicals & Pharmaceuticals is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.

The company?s consolidated net profit rose marginally by 0.2% to Rs 20.58 crore, while net sales increased 10.9% to Rs 580.39 crore in Q3 FY26 compared with Q3 FY25.

The counter dropped 1.77% to Rs 70 on the BSE.

Powered by Capital Market - Live News